Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Chemistry

Abstract #670: Anti-angiogenic and antitumor activity of XMT-1107, a fumagillin-derived polymer conjugate, and its in vivo release product XMT-1191

Laura Akullian, Cheri Stevenson, Tim Lowinger and Robert Fram
Laura Akullian
Mersana Therpeutics, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheri Stevenson
Mersana Therpeutics, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Lowinger
Mersana Therpeutics, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Fram
Mersana Therpeutics, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

XMT-1107, a fumagillin-derived polymer conjugate, and XMT-1191, the in vivo release product of XMT-1107, were evaluated for (1) biochemical activity in a metAP2 inhibition assay, (2) anti-angiogenic activity in a matrigel plug study in mice, and (3) anti-tumor activity in a Caki-1 renal cell carcinoma human tumor xenograft (HTX) model in mice, and their activities were compared with known anti-angiogenic and anti-tumor agents. XMT-1191 displayed potent inhibition against human metAP2 in vitro, in contrast to XMT-1107 which was >50 fold less active. In addition, XMT-1107 caused a decrease in angiogenesis when administered intravenously (iv) to mice in a matrigel plug assay. Lastly, in a Caki-1 HTX study, XMT-1107 exhibited superior activity compared to XMT-1191, as well as compared to known efficacious doses of TNP-470 or sunitinib. Methods: To evaluate the ability of XMT-1107 and XMT-1191 to inhibit human metAP2 enzyme, compounds were incubated with human metAP2 (6 nM) in a buffered medium after which Met-Gly-Pro-AMC was added and release of AMC measured with a Decan Plate reader at 30 sec intervals over 30 min. To evaluate the anti-angiogenic properties of XMT-1107 and XMT-1191, C57BL/6 female mice were implanted with 500 \#956;L matrigel, subcutaneous (sc), containing FGFb and heparin and treated with XMT-1107 or XMT-1191 for 11 days. Plugs were harvested and their microvessel and hemoglobin content quantified. To evaluate the anti-tumor activity of XMT-1107 and XMT-1191, HRLN female mice with sc tumors were treated with XMT-1107, XMT-1191, TNP-470, and sunitinib. Tumor sizes and body weights were monitored for 60 days and tumor growth delays were evaluated. Conclusions: XMT-1107 has enhanced anti-angiogenic and anti-tumor activity compared to its in vivo release product XMT-1191. We hypothesize that conjugation of XMT-1191 to poly(1-hydroxymethylethylene hydroxymethyl formal) (PHF) provides superior tissue distribution and pharmacokinetics resulting in enhanced biologic activity compared to administration of XMT-1191 alone. Additionally, the activity of XMT-1191 against human metAP2 in vitro was significantly greater than the activity of XMT-1107, which does not release significant amounts of XMT-1191 under the assay conditions. The enhanced anti-angiogenic, and in vivo anti-tumor activity of XMT-1107 compared to XMT-1191 demonstrates the utility of conjugating XMT-1191 to PHF. In addition, XMT-1107 has enhanced anti-cancer activity compared to known anti-angiogenic agents TNP-470 and clinically effective sunitinib in a Caki-1 HTX model. In conclusion, the anti-tumor and anti-angiogenic properties of XMT-1107 and the biochemical activity of XMT-1191 support the potential clinical utility of XMT-1107 as an anti-cancer agent.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 670.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #670: Anti-angiogenic and antitumor activity of XMT-1107, a fumagillin-derived polymer conjugate, and its in vivo release product XMT-1191
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract #670: Anti-angiogenic and antitumor activity of XMT-1107, a fumagillin-derived polymer conjugate, and its in vivo release product XMT-1191
Laura Akullian, Cheri Stevenson, Tim Lowinger and Robert Fram
Cancer Res May 1 2009 (69) (9 Supplement) 670;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #670: Anti-angiogenic and antitumor activity of XMT-1107, a fumagillin-derived polymer conjugate, and its in vivo release product XMT-1191
Laura Akullian, Cheri Stevenson, Tim Lowinger and Robert Fram
Cancer Res May 1 2009 (69) (9 Supplement) 670;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Chemistry

  • Abstract 6550: WD105, a novel decursin derivative, showed greater growth inhibition and androgen receptor suppression in LNCaP human prostate cancer cells
  • Abstract 5696: Genetic reprogramming of TAMs by engineered exosomes results in potent single agent anti-tumor activity
  • Abstract 5709: Disruption of mitochondrial metabolism underlies the efficacy of devimistat in acute myeloid leukemia
Show more Cancer Chemistry

Drug Design -- Poster Presentations - Proffered Abstracts

  • Abstract #674: Small molecules that target the nuclear export signal of topoisomerase II alpha for the treatment of multiple myeloma
  • Abstract #672: Biochemical mechanism of 3-Acetamidophenol toxicity in human SK-MEL-28 melanoma cells
  • Abstract #656: The design of combination chemotherapeutic potential in single agents
Show more Drug Design -- Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement